Evidence map›Paper›PMID 39180224›Full record

ArticleAllergy2025

Aspirin hypersensitivity diagnostic index (AHDI): In vitro test for diagnosing of N-ERD based on urinary 15-oxo-ETE and LTE

Lucyna Mastalerz, Gabriela Trąd, Piotr Szatkowski, Adam Ćmiel, Anna Gielicz, Radosław Kacorzyk, Hanna Plutecka, Joanna Szaleniec, Agnieszka Gawlewicz-Mroczka, Bogdan Jakieła and 1 more

Abstract read
In one paragraph

Article in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Clinical and mechanistic advancements in aspirin exacerbated respiratory disease.The Journal of allergy and clinical immunology · 2025
    Review
  8. Advances in the use of nanotechnology for treating gout.Nanomedicine (London, England) · 2025
    Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lucyna Mastalerz2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.ORCID https://orcid.org/0000-0002-8994-0036
Gabriela Trąd2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.
Piotr Szatkowski2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.
Adam ĆmielDepartment of Applied Mathematics, AGH University of Science and Technology, Krakow, Poland.
Anna Gielicz2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.ORCID https://orcid.org/0000-0002-2128-2145
Radosław Kacorzyk2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.
Hanna Plutecka2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.
Joanna SzaleniecDepartment of Otolaryngology, Jagiellonian University Medical College, Krakow, Poland.
Agnieszka Gawlewicz-Mroczka2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.
Bogdan Jakieła2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.
Marek Sanak2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.ORCID https://orcid.org/0000-0001-7635-8103

Funding

Narodowe Centrum Nauki
6 · The paper itself

Abstract

background15-oxo-eicosatetraenoic acid (15-oxo-ETE), is a product of arachidonic acid (AA) metabolism in the 15-lipoxygenase-1 (15-LOX-1) pathway. 15-oxo-ETE was overproduced in the nasal polyps of patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD). In this study we investigated the systemic biosynthesis of 15-oxo-ETE and leukotriene E

methodsThe study included 64 patients with N-ERD, 59 asthmatics who tolerated aspirin well (ATA), and 51 healthy controls. A thorough clinical characteristics of asthmatics included computed tomography of paranasal sinuses. Plasma and urinary 15-oxo-ETE levels, and urinary LTE

resultsPlasma 15-oxo-ETE levels were the highest in N-ERD (p < .001). A receiver operator characteristic (ROC) revealed that 15-oxo-ETE had certain sensitivity (64.06% in plasma, or 88.24% in urine) for N-ERD discrimination, while the specificity was rather limited. Modeling of variables allowed to construct the Aspirin Hypersensitivity Diagnostic Index (AHDI) based on urinary LTE

conclusionsWe confirmed 15-oxo-ETE as a second to cysteinyl leukotrienes biomarker of N-ERD. An index based on these eicosanoids corrected for sex and Lund-Mackay score has a similar diagnostic value as gold standard oral aspirin challenge in the studied group of patients with asthma.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalArachidonic AcidsAspirinAsthma, Aspirin-InducedDrug HypersensitivityLeukotriene E4AdultAgedBiomarkersFemaleHumansHydroxyeicosatetraenoic AcidsMaleMiddle AgedROC Curve15-hydroxy-5,8,11,13-eicosatetraenoic acidAnti-Inflammatory Agents, Non-SteroidalArachidonic AcidsAspirinBiomarkersHydroxyeicosatetraenoic AcidsLeukotriene E415‐oxo‐eicosatetraenoic acidaspirin hypersensitivity diagnostic indexin‐vitro diagnostic testNSAID‐exacerbated respiratory disease

Identifiers

PMID39180224
PMCPMC11804310

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.